Literature DB >> 8043421

Anticardiolipin antibodies in rheumatoid arthritis: their relation to rheumatoid nodules and cutaneous vascular manifestations.

P Wolf1, J Gretler, F Aglas, P Auer-Grumbach, F Rainer.   

Abstract

One hundred and seventy-three consecutive patients with rheumatoid arthritis were examined for the presence of anticardiolipin antibodies (ACA), and for the clinical relevance and the relation of these antibodies to skin manifestations. Abnormally elevated IgG- and/or IgM-ACA levels were detected by an enzyme-linked immunosorbent assay in the sera of 55 (32%) patients. There was no statistical evidence of an association between ACA and a history of thrombosis in these patients. However, ACA were statistically significantly linked to the presence of rheumatoid nodules, which were found in 36 (21%) patients. In three patients, ACA were associated with vascular manifestations, including livedo reticularis, thrombophlebitis, and leucocytoclastic vasculitis. Our findings suggest that, although a subset of ACA may be linked to cutaneous vascular conditions, the major fraction of ACA in rheumatoid arthritis may have a different specificity than in other diseases, in which ACA are often linked to thrombotic events.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8043421     DOI: 10.1111/j.1365-2133.1994.tb08456.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  12 in total

1.  Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.

Authors:  T Jonsdottir; J Forslid; A van Vollenhoven; A Harju; S Brannemark; L Klareskog; R F van Vollenhoven
Journal:  Ann Rheum Dis       Date:  2004-04-05       Impact factor: 19.103

Review 2.  The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis.

Authors:  Ewa Olech; Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

3.  Prevalence of antiphospholipid antibodies in Chilean patients with rheumatoid arthritis.

Authors:  Iván Palomo; Carmen Pinochet; Marcelo Alarcón; Rodrigo Sandoval; Jaime Gonzalez; Francisco Monsalves; Ricardo Forastiero
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

4.  Extra-articular manifestations of seronegative and seropositive rheumatoid arthritis.

Authors:  Vjollca Sahatciu-Meka; Sylejman Rexhepi; Suzana Manxhuka-Kerliu; Mjellma Rexhepi
Journal:  Bosn J Basic Med Sci       Date:  2010-02       Impact factor: 3.363

5.  Etanercept and venous thromboembolism: a case series.

Authors:  Ashima Makol; Madhusudan Grover; Carla Guggenheim; Houria Hassouna
Journal:  J Med Case Rep       Date:  2010-01-15

6.  Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.

Authors:  Fabiola Atzeni; Piercarlo Sarzi-Puttini; Donata Dell' Acqua; Simona de Portu; Germana Cecchini; Carola Cruini; Mario Carrabba; Pier Luigi Meroni
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

7.  Antiphospholipid antibodies during 6-month treatment with infliximab: a preliminary report.

Authors:  Bogdan Kolarz; Maria Majdan; Dorota A Darmochwal-Kolarz; Magdalena Dryglewska
Journal:  Med Sci Monit       Date:  2014-07-16

8.  The coexistence of antiphospholipid syndrome and systemic lupus erythematosus in Colombians.

Authors:  Juan-Sebastian Franco; Nicolás Molano-González; Monica Rodríguez-Jiménez; Yeny Acosta-Ampudia; Rubén D Mantilla; Jenny Amaya-Amaya; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

9.  Dimerized Domain V of Beta2-Glycoprotein I Is Sufficient to Upregulate Procoagulant Activity in PMA-Treated U937 Monocytes and Require Intact Residues in Two Phospholipid-Binding Loops.

Authors:  Alexey Kolyada; David A Barrios; Natalia Beglova
Journal:  Antibodies (Basel)       Date:  2017-06-02

Review 10.  Mitochondria-Derived Damage-Associated Molecular Patterns in Neurodegeneration.

Authors:  Heather M Wilkins; Ian W Weidling; Yan Ji; Russell H Swerdlow
Journal:  Front Immunol       Date:  2017-04-26       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.